Pyrotinib
Oligometastatic Prostate Cancer
The First Affiliated Hospital of Xiamen UniversitySmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
3 Active assets in the Oligometastatic Prostate Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Tislelizumab The First Affiliated Hospital of Xiamen University | Phase 2 | CCC |
Quemliclustat Catherine Spina | Phase 2 | CCC |
Goserelin Microspheres For The First Affiliated Hospital of Xiamen University | Phase 2 | CCC |
Same molecule, other indications
Pyrotinib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →